ERBB3 and neoplasm: As prostate tumours develop resistance therapy through compensatory pathways regulating ErbB3 expression and localization, anti-ErbB3 therapeutic antibodies could be used for tumours displaying ErbB3185kDa overexpression and/or nuclear localization but not for tumour expressing ErbB380kDa [17, 25].